ReviewInternational journal of chronic obstructive pulmonary disease2022
From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis.
Review in International journal of chronic obstructive pulmonary disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07543601 (Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention), which is not on this map. Cited by 63 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention
Who cites it
63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Frontiers in immunology · 2025Pooled it
- Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Global, regional, and national trends in burden of lung cancer and chronic obstructive pulmonary disease and associated risk factors, 1990-2021: results from the global burden of disease study 2021.NPJ primary care respiratory medicine · 2026Article
- IL-8 drives EMT and malignant progression in chronic obstructive pulmonary disease-associated lung cancer via STAT3 signaling.Cell division · 2026Article
- USP7-dependent stabilization of FKBP4 contributes to acquired osimertinib resistance through glycolytic remodeling in NSCLC.Scientific reports · 2026Article
- The Role of Cellular Senescence in Obstructive Airway Diseases: From Mechanisms to Therapeutic Targets.International journal of molecular sciences · 2026Review
- Comorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe.The Lancet regional health. Europe · 2026Article
- Article
- Regulatory role of IL-17-mediated inflammatory pathways in lung cancer initiation and progression.Discover oncology · 2026Review
- Article
- Observational
- Integrating central-slice anatomy and MRF-mapped radiomics dynamics for lung adenocarcinoma subtyping.Quantitative imaging in medicine and surgery · 2026Article
- Predictive value of CT target scan-based radiomics and clinical features for patients with chronic obstructive pulmonary disease combined with malignant pulmonary nodules.Biomedical engineering online · 2026Article
- Integrating Machine Learning for Early COPD Prediction in Lung Cancer Patients: A Focus on Systemic Coagulation-Inflammation Index.International journal of chronic obstructive pulmonary disease · 2026Article
- Gut microbiota dysbiosis in COPD patients increases the level of queuine in the blood serum abnormally enhancing the viability of lung epithelial cells.Frontiers in immunology · 2026Article
- Formation and remodeling of immunological niches in solid tumors: organ-specific architectures, inflammatory parallels, and therapeutic reprogramming.Frontiers in immunology · 2026Review
- SHAP-interpretable machine learning integrating exposures and multi-omics reveals immune alterations and biomarkers in COPD-lung cancer comorbidity.Frontiers in immunology · 2026Article
- Respiratory omics for early detection of COPD-to-lung cancer transition: mechanisms, biomarkers and clinical translation.Frontiers in cell and developmental biology · 2026Review
- Association Between Chronic Obstructive Pulmonary Disease and Survival in Patients with Lung Cancer: A Nationwide Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies have proved that the pathogenesis of the chronic obstructive pulmonary disease (COPD) and lung cancer is related, and may cause and affect each other to a certain extent. In fact, the change of chronic airway obstruction will continue to have an impact on the screening, treatment, and prognosis of lung cancer.In this comprehensive review, we outlined the links and heterogeneity between COPD and lung cancer and finds that factors such as gene expression and genetic susceptibility, epigenetics, smoking, epithelial mesenchymal transformation (EMT), chronic inflammation, and oxidative stress injury may all play a role in the process. Although the relationship between these two diseases have been largely determined, the methods to prevent lung cancer in COPD patients are still limited. Early diagnosis is still the key to a better prognosis. Thus, it is necessary to establish more intuitive screening evaluation criteria and find suitable biomarkers for lung cancer screening in high-risk populations with COPD. Some studies have indicated that COPD may change the efficacy of anti-tumor therapy by affecting the response of lung cancer patients to immune checkpoint inhibitors (ICIs). And for lung cancer patients with COPD, the standardized management of COPD can improve the prognosis. The treatment of lung cancer patients with COPD is an individualized, comprehensive, and precise process. The development of new targets and new strategies of molecular targeted therapy may be the breakthrough for disease treatment in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.